Table 2 Comparison of patient demographic and clinical tumor characteristics between the training cohort and validation cohort

Sex

0.402^a

 Male

26(70.3)

15(60.0)

 Female

11(29.7)

10(40.0)

Age(year)

64.35 ± 10.71

61.16 ± 10.85

0.257^b

Tumor location

0.473^a

 Colon or sigmoid colon

25(67.6)

19(76.0)

 Rectum or rectosigmoid junction

12(32.4)

6(24.0)

Differentiation

0.933^a

 Well/moderate

27(73.0)

18(72.0)

 Poor

10(27.0)

7(28.0)

TNM stage

0.640^a

 I-II

17(45.9)

13(52.0)

 III-IV

20(54.1)

12(48.0)

CEA

0.498^a

 < 5.0 ng/ml

21(56.8)

12(48.0)

 ≥ 5.0 ng/ml

16(43.2)

13(52.0)

Mutational status

0.953^a

 KRAS/NRAS/BRAF mutated

21(56.8)

14(56.0)

 Wild type

16(43.2)

11(44.0)